Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 8 Issue 4, April 2012

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Research Highlight

Top of page ⤴

News & Views

  • A recently published study on therapy for antineutrophil cytoplasmic autoantibody-associated small vessel vasculitis has provided answers but not clarity towards defining how best to treat patients with vasculitis. How do we use recent advances in knowledge to optimally influence our patients' outcomes without causing harm in the process?

    • JulieAnne G. McGregor
    • Ronald J. Falk
    News & Views
  • In an era of increased concern about the safety of using erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease, findings from the CAPRIT trial have suggested that ESA administration to correct anemia may slow the progression of kidney allograft dysfunction.

    • Edmund Huang
    • Suphamai Bunnapradist
    News & Views
  • Acute kidney injury (AKI) is a common complication associated with increased patient mortality and progression to advanced chronic kidney disease. Mehrotra et al. recently investigated the incidence and long-term sequelae of AKI in a large cohort of kidney transplant recipients.

    • Edward J. Nehus
    • Prasad Devarajan
    News & Views
  • The combined effect of intensive glycemic and blood-pressure control on microvascular complications has been examined in an analysis of the ACCORD study. The investigators hypothesized that simultaneous intensive management would have an additive effect on outcomes; however, the results provide no evidence to support the combined intensive control of glycemia and blood pressure.

    • Luis M. Ruilope
    News & Views
  • Recent analyses from the FIELD randomized trial of fenofibrate in type 2 diabetes mellitus suggests that fibrates have beneficial effects and are safe in patients with moderate renal impairment. However, too few participants with chronic kidney disease were included in the study to provide reliable information.

    • David Lewis
    • Christoph Wanner
    News & Views
Top of page ⤴

Review Article

  • Considerable advances in our understanding of the molecular pathomechanisms of membranous nephropathy have been made over the past few years. In this Review, Ronco and Debiec provide an update on antigen–antibody systems involved in membranous nephropathies. The authors discuss experimental models that have helped elucidate systems involved in human disease, recent advances in this field as well as new therapies and future challenges.

    • Pierre Ronco
    • Hanna Debiec
    Review Article
  • Accelerated cardiovascular disease is a major cause of death in patients with chronic kidney disease (CKD) and treatment with statin therapy is an important avenue for investigation. Here, Epstein and Vaziri discuss the pathogenesis of dyslipidemia in CKD and end-stage renal disease (ESRD), and examine the findings from three major clinical trials on statin therapy in patients with CKD and ESRD.

    • Murray Epstein
    • Nosratola D. Vaziri
    Review Article
  • Use of peritoneal dialysis therapy, with or without newer 'biocompatible' peritoneal dialysis solutions, is associated with an improvement in patient survival that is equivalent to that obtained with hemodialysis. In this Review, the authors compare conventional and newer peritoneal dialysis solutions in terms of their documented impact on the peritoneum and effects such as removal of sodium and fluid, metabolic alterations, risk of cardiovascular disease and infections, and patient survival.

    • Elvia García-López
    • Bengt Lindholm
    • Simon Davies
    Review Article
  • Renal impairment is a common problem in patients with multiple myeloma. An early and rapid reduction in serum levels of free light chains (FLCs), achieved with the use of antimyeloma agents or direct removal of FLCs, has been shown to improve renal recovery in these patients. In this Review, the authors provide an update on new and current management approaches for reducing FLC levels in patients with myeloma-related acute kidney injury.

    • Colin A. Hutchison
    • Joan Bladé
    • Christopher Winearls
    Review Article
Top of page ⤴

Opinion

  • Revascularization alone might be sufficient to restore kidney function and regenerate the structure of the diseased kidney. In this Perspectives article, David Long, Jill Norman and Leon Fine provide an overview of how revascularization might be achieved using vascular growth factors or adoptive transfer of endothelial progenitor cells. The authors also describe how therapeutic strategies targeting the microvasculature could be enhanced in the future.

    • David A. Long
    • Jill T. Norman
    • Leon G. Fine
    Opinion
Top of page ⤴

Search

Quick links